ADC’s Label-Expansion Study For Zynlonta Halted For Respiratory Safety

 
• By Joseph Haas
  
Clinical trial
ADC Therapeutics halts Zynlonta study for safety issues, but other trials continue • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D